{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:39Z","timestamp":1781643279100,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U54 program","award":["EACHC-444"],"award-info":[{"award-number":["EACHC-444"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant concurrent chemoradiotherapy following radical hysterectomy is the cornerstone of curative-intent treatment for early-stage cervical cancer. However, among people living with Human Immunodeficiency Virus (PLWHIV) and cervical cancer, the interplay of treatment toxicity, immunosuppression and systemic health barriers presents a compounded clinical challenge. Evidence on how HIV infection influences baseline clinical patterns and prognosis following standard multimodal therapy remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a descriptive retrospective cohort review of women with FIGO 2018 stage IA\u2013IIA cervical cancer who had completed curative-intent trimodal therapy (adjuvant pelvic external-beam radiotherapy (45\u201350.4\u00a0Gy), weekly cisplatin (40\u00a0mg\/m\u00b2), and brachytherapy following radical hysterectomy (type II\/III) with pelvic lymphadenectomy) between 2014 and 2023, at a tertiary referral hospital in Kenya. The baseline clinicopathological characteristics, treatment-related toxicities, 3-year disease-free survival (DFS), and 5-year overall survival (OS) were described. Results were stratified by HIV status. Survival analysis was conducted using Kaplan-Meier estimates and log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over the 10-year study period, 275 patients with cervical cancer underwent radical hysterectomy with bilateral pelvic lymphadenectomy. Of 62 patients meeting criteria for adjuvant therapy (17 PLWHIV, 45 HIV-negative), 38 (61.3%) completed trimodal therapy. This corresponded to a completion rate of 76.5% (13\/17) among PLWHIV versus 55.6% (25\/45) among HIV-negative patients. Baseline clinicopathological profiles, including age, performance status, and histology (squamous cell carcinoma: 100% versus 88.0%) did not differ substantially between groups. Positive lymph nodes were the most common high-risk feature (53.8% versus 40.0%), and lymphovascular space invasion (LVSI) was the predominant intermediate-risk feature (69.2% versus 40.0%). Median time from surgery to adjuvant therapy initiation was 77.5 days (IQR 42\u2013210). Lymphedema (21.1%) and bladder dysfunction (18.4%) were the frequently reported any-grade chronic toxicities. Myelosuppression occurred in 23.1% versus 4.0%. The 3-year DFS was 53.8% among PLWHIV and 77.6% among HIV-negative patients (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14); median OS was 14.5 months versus 21.1 months (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12). Five-year survival estimates were not attainable for PLWHIV due to early recurrence and mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite comparable baseline characteristics, PLWHIV showed a nonsignificant trend toward greater treatment-related toxicity and reduced survival following trimodal therapy for early-stage cervical cancer. These findings underscore the importance of regional strengthening of HIV-oncology integrated services, and generating prospective research on optimum management strategies for this vulnerable cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15761-5","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:53:22Z","timestamp":1773021202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing trimodal therapy outcomes by HIV status in early-stage cervical cancer: a retrospective cohort study from a Kenyan tertiary centre"],"prefix":"10.1186","volume":"26","author":[{"given":"Gabriel Eliazaro","family":"Ouma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimbley","family":"Asaso Omwodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Itsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Amubuomombe","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanguru","family":"Wahome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odhiambo","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasengo","family":"Chiriswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Green Harris","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adagi","family":"Awuor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Covens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Tonui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"2","key":"15761_CR1","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8(2):e191\u2013203.","journal-title":"Lancet Global Health"},{"issue":"2","key":"15761_CR2","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. lancet global health. 2023;11(2):e197\u2013206.","journal-title":"lancet global health"},{"issue":"2","key":"15761_CR3","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","volume":"9","author":"D Stelzle","year":"2021","unstructured":"Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah AS, McAllister DA, Gottlieb SL, Klug SJ, Winkler AS. Estimates of the global burden of cervical cancer associated with HIV. lancet global health. 2021;9(2):e161\u20139.","journal-title":"lancet global health"},{"key":"15761_CR4","doi-asserted-by":"publisher","first-page":"957325","DOI":"10.3389\/fonc.2022.957325","volume":"12","author":"D Mrema","year":"2023","unstructured":"Mrema D, Ngocho JS, Mremi A, Amour M, Machange R, Shayo BC, Alloyce JP, Ndosi E, Shirima BT, Fande D. Cervical cancer in Northern Tanzania\u2014What do women living with HIV know. Front Oncol. 2023;12:957325.","journal-title":"Front Oncol"},{"issue":"9","key":"15761_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/cam4.485","volume":"4","author":"A Ntekim","year":"2015","unstructured":"Ntekim A, Campbell O, Rothenbacher D. Optimal management of cervical cancer in HIV-positive patients: a systematic review. Cancer Med. 2015;4(9):1381\u201393.","journal-title":"Cancer Med"},{"issue":"3","key":"15761_CR6","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.3802\/jgo.2017.28.e34","volume":"28","author":"F Landoni","year":"2017","unstructured":"Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB\u2013IIA cervical cancer: 20-year update. J gynecologic Oncol. 2017;28(3):e34.","journal-title":"J gynecologic Oncol"},{"issue":"3","key":"15761_CR7","first-page":"87","volume":"32","author":"P Tonui","year":"2020","unstructured":"Tonui P, Itsura P, Omenge E, Mburu A, Odongo E, Keter A, Muliro H, van Lonkhuijzen LR, Covens A, Rosen B. Radical surgery for early cervical cancer in a resource limited setting: survival and challenges. J Obstet Gynecol East Cent Afr. 2020;32(3):87.","journal-title":"J Obstet Gynecol East Cent Afr"},{"issue":"6","key":"15761_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/COC.0b013e3181cae5b7","volume":"33","author":"H Yamashita","year":"2010","unstructured":"Yamashita H, Okuma K, Kawana K, Nakagawa S, Oda K, Yano T, Kobayashi S, Wakui R, Ohtomo K, Nakagawa K. Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol. 2010;33(6):583\u20136.","journal-title":"Am J Clin Oncol"},{"key":"15761_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/GO.21.00081","volume":"7","author":"S Mohanty","year":"2021","unstructured":"Mohanty S, Gurram L, Chopra S, Mahantshetty U, Grover S. Cervical cancer treatment in PLWHIV patients: A survey of treatment practices in India. JCO Global Oncol. 2021;7:843\u20138.","journal-title":"JCO Global Oncol"},{"issue":"8","key":"15761_CR10","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(18)30342-5","volume":"19","author":"B Sirohi","year":"2018","unstructured":"Sirohi B, Chalkidou K, Pramesh CS, Anderson BO, Loeher P, El Dewachi O, Shamieh O, Shrikhande SV, Venkataramanan R, Parham G. Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres. Lancet Oncol. 2018;19(8):e395\u2013406.","journal-title":"Lancet Oncol"},{"issue":"2","key":"15761_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/gyno.1999.5387","volume":"73","author":"A Sedlis","year":"1999","unstructured":"Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177\u201383.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"15761_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"IIIWA Peters","year":"2000","unstructured":"Peters IIIWA, Liu P, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606\u201313.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15761_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","volume":"65","author":"M Rotman","year":"2006","unstructured":"Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiation Oncology* Biology* Phys. 2006;65(1):169\u201376.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"15761_CR14","doi-asserted-by":"publisher","unstructured":"Putri NQ, Permata TBM, Wulandari NA, Handoko, Nuryadi E, Purwoto G, Gondhowiardjo SA. Relationship of adherence to cervical cancer treatment guideline towards patients\u2019 five-year survival: systematic review of follow-up trials. Cancer Manag Res. 2020:12649\u201355. https:\/\/doi.org\/10.2147\/CMAR.S267824.","DOI":"10.2147\/CMAR.S267824"},{"key":"15761_CR15","doi-asserted-by":"publisher","unstructured":"Hanprasertpong J, Jiamset I, Geater A, Leetanaporn K, Peerawong T. Impact of time interval between radical hysterectomy with pelvic node dissection and initial adjuvant therapy on oncological outcomes of early stage cervical cancer. J Gynecol Oncol. 2017;28(4). https:\/\/doi.org\/10.3802\/jgo.2017.28.e42.","DOI":"10.3802\/jgo.2017.28.e42"},{"key":"15761_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2021.02.013","volume":"148","author":"K Matsuo","year":"2021","unstructured":"Matsuo K, Shimada M, Matsuzaki S, Enomoto T, Mikami M. Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: a treatment implication during the coronavirus pandemic. Eur J Cancer. 2021;148:117\u201320.","journal-title":"Eur J Cancer"},{"key":"15761_CR17","unstructured":"NyandikoW, Siika A, Ernst JA, Ettyang G, Neumann C, Yiannoutsos C. The Academic Model Providing Access To Healthcare (AMPATH) in Kenya. 2008. https:\/\/scholarworks.indianapolis.iu.edu\/server\/api\/core\/bitstreams\/5b6efdb1-c6b9-496a-9687-17fec80645d4\/content."},{"issue":"7","key":"15761_CR18","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/IGC.0000000000001307","volume":"28","author":"K-Y You","year":"2018","unstructured":"You K-Y, Zhou X-H, Jiang Y-H, Bi Z-F, Liu Y-M, Qiu X-S. The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cance. Int J Gynecol Cancer. 2018;28(7):1325\u201332.","journal-title":"Int J Gynecol Cancer"},{"key":"15761_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.gore.2017.01.009","volume":"20","author":"C Nakisige","year":"2017","unstructured":"Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecologic Oncol Rep. 2017;20:37\u201340.","journal-title":"Gynecologic Oncol Rep"},{"issue":"3","key":"15761_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ijgo.13004","volume":"148","author":"IM Peter","year":"2020","unstructured":"Peter IM, Deraney RN, Orango O, Philip T, Rosen B, Cu-Uvin S. Radical hysterectomy for operable early cervical cancer in HIV\u2010positive and HIV\u2010negative women in western Kenya. Int J Gynecol Obstet. 2020;148(3):403\u20134.","journal-title":"Int J Gynecol Obstet"},{"key":"15761_CR21","unstructured":"Musalia WA. A Review of Radical Hysterectomy as Primary Treatment for Early Stage Cervical Cancer at KNH 2013\u20132018. 2021."},{"issue":"35","key":"15761_CR22","doi-asserted-by":"publisher","first-page":"e27030","DOI":"10.1097\/MD.0000000000027030","volume":"100","author":"MM Mohosho","year":"2021","unstructured":"Mohosho MM. HIV prevalence in patients with cervical carcinoma: A cohort study at a secondary hospital in South Africa. Medicine. 2021;100(35):e27030.","journal-title":"Medicine"},{"issue":"2","key":"15761_CR23","first-page":"37","volume":"8","author":"S Mdletshe","year":"2016","unstructured":"Mdletshe S, Munkupa H, Lishimpi K. Acute toxicity in cervical cancer PLWHIV vs. HIV-negative patients treated by radical chemo-radiation in Zambia. South Afr J Gynaecol Oncol. 2016;8(2):37\u201341.","journal-title":"South Afr J Gynaecol Oncol"},{"key":"15761_CR24","doi-asserted-by":"publisher","first-page":"101069","DOI":"10.1016\/j.gore.2022.101069","volume":"43","author":"YQ Turdo","year":"2022","unstructured":"Turdo YQ, Ruffieux Y, Boshomane TM, Mouton H, Taghavi K, Haas AD, Egger M, Maartens G, Rohner E. Cancer treatment and survival among cervical cancer patients living with or without HIV in South Africa. Gynecologic Oncol Rep. 2022;43:101069.","journal-title":"Gynecologic Oncol Rep"},{"issue":"3","key":"15761_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/IGC.0b013e31828703fd","volume":"23","author":"M Okazawa","year":"2013","unstructured":"Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, Ohta Y, Kamiura S, Ogawa K, Kimura T. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013;23(3):567\u201375.","journal-title":"Int J Gynecol Cancer"},{"key":"15761_CR26","doi-asserted-by":"publisher","first-page":"100516","DOI":"10.1016\/j.gore.2019.100516","volume":"31","author":"ES Wu","year":"2020","unstructured":"Wu ES, Urban RR, Krantz EM, Mugisha NM, Nakisige C, Schwartz SM, Gray HJ, Casper C. The association between HIV infection and cervical cancer presentation and survival in Uganda. Gynecologic Oncol Rep. 2020;31:100516.","journal-title":"Gynecologic Oncol Rep"},{"issue":"4","key":"15761_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/QAD.0000000000001367","volume":"31","author":"MP Ferreira","year":"2017","unstructured":"Ferreira MP, Coghill AE, Chaves CB, Bergmann A, Thuler LC, Soares EA, Pfeiffer RM, Engels EA, Soares MA. Outcomes of cervical cancer among PLWHIV and HIV-uninfected women treated at the Brazilian National Institute of Cancer. Aids. 2017;31(4):523\u201331.","journal-title":"Aids"},{"issue":"1","key":"15761_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13027-021-00389-w","volume":"16","author":"E MacDuffie","year":"2021","unstructured":"MacDuffie E, Bvochora-Nsingo M, Chiyapo S, Balang D, Chambers A, George JM, Tuli S, Lin LL, Zetola NM, Ramogola-Masire D. Five-year overall survival following chemoradiation therapy for locally advanced cervical carcinoma in women living with and without HIV infection in Botswana. Infect Agents Cancer. 2021;16(1):55.","journal-title":"Infect Agents Cancer"},{"key":"15761_CR29","doi-asserted-by":"publisher","unstructured":"Aksak-W\u0105s B, Skonieczna-\u017bydecka K, Parczewski M, Hrynkiewicz R, Lewandowski F, Serwin K, Mielczak K, Majchrzak A, Bruss M, Nied\u017awiedzka-Rystwej P. Immunorecovered but Exhausted: Persistent PD-1\/PD-L1 Expression Despite Virologic Suppression and CD4 Recovery in PLWH. Biomedicines. 2025;13(8). https:\/\/doi.org\/10.3390\/biomedicines13081885.","DOI":"10.3390\/biomedicines13081885"},{"key":"15761_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3332\/ecancer.2025.1879","volume":"19","author":"S Dadheech","year":"2025","unstructured":"Dadheech S, Burde K, Dave P, Arora R, Parekh C. Post treatment lower limb lymphedema in carcinoma cervix. Ecancermedicalscience. 2025;19:1879.","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"15761_CR31","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/IGC.0b013e3181da29d0","volume":"20","author":"MJ Halaska","year":"2010","unstructured":"Halaska MJ, Novackova M, Mala I, Pluta M, Chmel R, Stankusova H, Robova H, Rob L. A prospective study of postoperative lymphedema after surgery for cervical cancer. Int J Gynecol Cancer. 2010;20(5):900\u20134.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"15761_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.21037\/tcr-22-1256","volume":"11","author":"H Hu","year":"2022","unstructured":"Hu H, Fu M, Huang X, Huang J, Gao J. Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis. Translational cancer Res. 2022;11(6):1713.","journal-title":"Translational cancer Res"},{"issue":"10","key":"15761_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/cancers11101471","volume":"11","author":"WI Chang","year":"2019","unstructured":"Chang WI, Kang H-C, Wu H-G, Kim HJ, Jeon SH, Lee M, Kim HS, Chung HH, Kim JW, Park NH. Lower extremity lymphedema in gynecologic cancer patients: propensity score matching analysis of external beam radiation versus brachytherapy. Cancers. 2019;11(10):1471.","journal-title":"Cancers"},{"issue":"1","key":"15761_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17425255.2024.2408004","volume":"21","author":"C Branch","year":"2025","unstructured":"Branch C, Parson-Martinez J, Cory TJ. Drug\u2013drug interactions in PLWHIV patients receiving chemotherapy. Expert Opin Drug Metab Toxicol. 2025;21(1):15\u201327.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15761-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:11:00Z","timestamp":1781640660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15761-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15761"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15761-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Moi University and Moi Teaching and Referral Hospital Institutional Research and Ethics Committee (IREC), approval number: 0004931. The IREC granted a waiver of informed consent for this study, as it involved secondary analysis of anonymized, routinely collected clinical data with minimal risk to participants. Additional approvals were obtained from MTRH administration and the National Commission for Science, Technology, and Innovation (NACOSTI; License number: NACOSTI\/P\/24\/414426).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"488"}}